PolyPeptide Group

About the company

Unclaimed editorial profile · compiled from public sources.

PolyPeptide Group is a contract development and manufacturing organization (CDMO) for peptide-based active pharmaceutical ingredients. It serves pharmaceutical and biotech companies with proprietary and generic products. Its website lists commercial manufacturing, process development and optimization, pre-GMP development, quality control and regulatory support, as well as custom research-grade and radiolabeled peptides. Company news items are datelined Baar, Switzerland. In 2026 Samsung Biologics, through its subsidiary Samsung Peptide AG, made a public tender offer for the company's shares. The company says it is a leader in peptide manufacturing.

Products & services

The company publicly describes the following offerings. Availability and suitability must be confirmed directly.

• Peptide API contract manufacturing
• Commercial manufacturing
• Process development and optimization
• Pre-GMP development
• Quality control and quality assurance
• Regulatory support
• Custom research-grade peptides
• Radiolabeled peptides
• Generic peptides

What the company says

These are the company’s own statements, not confirmed by Vetted Vial.

• Says it is a world leader in peptide manufacturing
• Says it supports both proprietary and generic peptide products

Public records

Oct 16, 2026: PolyPeptide reported that Samsung Biologics' public tender offer was declared successful (87.59% of shares tendered by Oct 12), with completion subject to regulatory approvals and expected end of 2026 or Q1 2027.

Source and review scope

Public website checked October 23, 2026. Profile compiled by Vetted Vial from public sources; not supplied or endorsed by the company. Official source.

Confirm current products, services, terms, and documentation directly with the company.